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Abstract
A serological survey for antibodies to inﬂuenza viruses was per-
formed in China on a group of people without a history of inﬂu-
enza vaccination. Using the haemagglutination inhibition (HI)
assay, we found seropositivity rates for seasonal H3N2 to be
signiﬁcantly higher than those for seasonal H1N1. Samples posi-
tive for antibodies to the pandemic (H1N1) 2009 virus increased
from 0.6% pre-outbreak to 4.5% (p <0.01) at 1 year post-out-
break. Interestingly, HI and neutralization tests showed that
1.4% of people in the group have antibodies recognizing H9N2
avian inﬂuenza viruses, suggesting that infection with this subtype
may be more common than previously thought.
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Serological data may provide information required for under-
standing general immunity, and retrospectively determining
the infection rate of previously-circulating strains of inﬂuenza
virus. The outbreak of the swine-origin pandemic (H1N1)
2009 virus led to numerous studies that revealed some varia-
tions in pre-existing or cross immunity to the pandemic
(H1N1) 2009 virus strain between people from different
regions [1–6]. These are most likely due to geopolitical dif-
ferences in access to annual inﬂuenza vaccination pro-
grammes, as well as past exposure to genetically-related
inﬂuenza virus strains. In addition to the seasonal inﬂuenza
viruses, including the 2009 H1N1 virus, human infections
caused by avian H5N1, H7N7 and H9N2 viruses have been
observed in recent years [7]. While infection with highly
pathogenic H5N1 and H7N7 strains causes severe disease,
infection with H9N2 virus results in mild symptoms, similar
to seasonal inﬂuenza. Avian H9N2 virus is highly prevalent in
poultry, particularly chickens, and has plenty of opportunities
for cross-species transmission. There is concern that
repeated avian-human transmissions may result in gradual
host adaptation of H9N2, leading to another pandemic. Esti-
mation of unrecognized infection in the general population is
therefore extremely important.
In this study, a serological survey of people from rural
areas of China was conducted in order to understand the
rate of natural infection with strains of inﬂuenza viruses that
are circulating in humans and also strains that are circulating
in poultry, but have the potential to cross the species barrier
and infect humans. A total of 1571 serum samples collected
in March 2009, prior to the outbreak of pandemic (H1N1)
2009 inﬂuenza, and a further 9936 serum samples collected
in May 2010, all from blood donors who were born between
1942 and 1991 and resident in Jiangsu Province in eastern
China, were analysed. Microwell cell neutralization assays
performed in Madin-Darby Canine Kidney (MDCK) cell cul-
tures and haemagglutination inhibition (HI) assays were used
to detect antibodies against inﬂuenza virus, as previously
described [8,9].
We ﬁrst examined 1039 sera collected from residents of
villages in Jiangsu Province in May 2010 for the presence of
antibodies to eight selected inﬂuenza viruses, using the HI
assay. As shown in Table 1, the positive rate (HI ‡ 40) for
the presence of antibodies to seasonal H1N1 virus is only
1.4% and the higher positive rate, 16.8%, for H3N2-speciﬁc
antibodies is likely to be attributed to the predominant circu-
lation of the A/Perth/16/09-like H3N2 strain from the 2009
season. The pandemic (H1N1) 2009 virus started to circulate
in China in June 2009. To ﬁnd the rate of natural infection
with pandemic (H1N1) virus among this group of people, we
examined sera for the presence of antibodies to
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A/California/7/09. Antibodies were detected in 3.1% of peo-
ple from this group. To better understand the rate of infec-
tion with the pandemic (H1N1) 2009 virus, 1571 sera
samples collected in March 2009, before the outbreak of the
pandemic, and all 9936 sera samples collected in May 2010
were compared. While only 0.6% of people sampled in
March 2009 exhibited positive antibodies to the A/California/
7/09 virus, the positive rate was 4.5% among sera samples
collected in 2010. We were able to further conﬁrm this
observation by examining 1295 sets of paired sera, each pair
consisting of samples from the same donors, taken in March
2009 and May 2010. As shown in Table 2, the positive rate
is 0.6% and 4.7% among the 2009 and 2010 sera samples,
respectively. These results suggest that the natural infection
rate with pandemic (H1N1) 2009 in rural areas of China
(3.1–4.7%) is well below the levels reported in other places
[3–5,10]. While reports from other studies, conducted
mainly in urban areas, found a drastic increase in seropositiv-
ity in humans following the peak period of pandemic (H1N1)
2009 virus circulation [3–5,10], only about 4.5% of people
sampled in this study exhibited detectable levels of antibodies
to this virus, suggesting that the majority of people in rural
areas of China are still naı¨ve, in terms of exposure to the
pandemic (H1N1) 2009 virus.
The 1039 sera initially described above were further
examined for antibodies to avian H5N1, H9N2 and H6N1
subtype viruses. Antigenically distinct strains of avian H5N1
virus are known to circulate in different places, causing spo-
radic human infections [8]. We used four H5N1 virus strains,
representing different antigenic groups, for the HI assays
conducted in this study. No positive samples (HI ‡ 40) were
found among the 1039 sera examined. Likewise, none of the
sera tested positive for antibodies to the H6 subtype avian
inﬂuenza virus. Genetic and antigenic analysis has revealed
that there are two lineages of H9N2 viruses, G1-like and
Ck/Bei-like, co-circulating in domestic poultry, and viruses
from both lineages have been reported to cause human
infections [11]. We therefore used viruses representing both
genetic lineages to conduct HI tests. In contrast to the
results for H5 and H6 subtype viruses, 1.4% of people tested
positive for antibodies to one of the H9N2 viruses. To con-
ﬁrm that the positive antisera were speciﬁc for the H9N2
virus, micro-neutralization assays were conducted, and dem-
onstrated that the antibodies detected by the HI assay do
TABLE 1. Prevalence of antibodies against different inﬂuenza A viruses in sera from unvaccinated people in Jiangsu, China
Subtype Virus strain
Positive number at different HI (rate, 95% CI) (n = 1039)
HI ‡ 10 HI ‡ 20 HI ‡ 40 HI ‡ 80
H1N1 Brisbane/59/2007 126 (12.1%, 10.2–14.3) 51 (4.9%, 3.7–6.4) 14 (1.4%, 0.7–2.2) 4 (0.4%, 0.1–1.0%)
panH1N1 California/07/2009 88 (8.5%, 6.9–10.3) 57 (5.5%, 4.2–7.0) 32 (3.1%, 2.1–4.3) 11 (1.1%, 0.5–1.9)
H3N2 Perth/16/2009-like 435 (41.9%, 38.8–44.9) 335 (32.2%, 29.4–35.2) 174 (16.8%, 14.5–19.2) 69 (6.6%, 5.2–8.3)
H5N1 Shenzhen/406H/2006 (Clade 2.3.4) 27 (2.6%, 1.7–3.8) 3 (0.3%, 0.1–0.8) 0 (0.0%, 0.0–0.4) 0 (0.0%, 0.0–0.4)
BGs/Qinghai/15C/2005 (Clade 2.2) 3 (0.3%, 0.1–0.8) 2 (0.2%, 0.0–0.7) 0 (0.0%, 0.0–0.4) 0 (0.0%, 0.0–0.4)
H9N2 A/HK/2103/03 9 (0.9%, 0.4–1.6) 1 (0.1%, 0.1–0.5) 0 (0.0%, 0.0–0.4) 0 (0.0%, 0.0–0.4)
A//HK//464419/09 149 (14.3%, 12.3–16.6) 62 (6.0%, 4.6–7.6) 15 (1.4%, 0.8–2.4) 3 (0.3%, 0.1–0.8)
H6N1 A/ duck/JX227/03 0 (0.0%, 0.0–0.4) 0 (0.0%, 0.0–0.4) 0 (0.0%, 0.0–0.4) 0 (0.0%, 0.0–0.4)
1039 sera samples with approximately 200 samples in each of ﬁve birth-year groups (1942–1951, 1952–1961, 1962–1971, 1972–1981, 1982–1991) were collected from resi-
dents of two villages in Jiangsu Province, China, in May 2010. Antibodies to reference strains of the inﬂuenza A virus were examined by haemagglutination inhibition assay
[9]. For the H5N1 virus, HI assays were also conducted using two strains belonging to clade 7: no positive reactions were detected. For H9N2, two strains representing the
G1 and CK/Bei lineages were used and all positive sera with HI ‡ 40 were tested against other major inﬂuenza virus subtypes to exclude cross-reactivity. Neutralization
assays were also performed to conﬁrm the presence of speciﬁc antibodies to H9 that did not cross-react with other subtypes of inﬂuenza virus. Specimens were tested in
duplicate. Estimation of the 95% conﬁdence interval was performed with exact binomial methods. BGs, bar-headed goose; A/HK/2103/03 (CK/Bei-like); A/HK/464419/09 (G1-
like).
TABLE 2. Serum antibodies to pandemic (H1N1) 2009 virus A/California/07/2009
Collection
place
Collection
date
No. of
subjects
Positive number at different HI (rate, 95% CI)
HI ‡ 10 HI ‡ 20 HI ‡ 40 HI ‡ 80
Jiangsua March 2009 1571 52 (3.3%, 2.5–4.3) 25 (1.6%, 1.0–2.3) 9 (0.6%, 0.3–1.1) 2 (0.1%, 0.0–0.5)
May 2010 9936 1385 (13.9%, 13.3–14.6)* 874 (8.8%, 8.2–9.4)* 448 (4.5%, 4.1–4.9)* 182 (1.8%, 1.6–2.1)*
Jiangsu serialb March 2009 1295 43 (3.3%, 2.4–4.4) 20 (1.5%, 1.0–2.4) 8 (0.6%, 0.3–1.2) 2 (0.2%, 0.0–0.6)
May 2010 1295 178 (13.8%, 11.9–15.7)* 119 (9.2%, 7.7–10.9)* 61 (4.7%, 3.6–6.0)* 24 (1.8%, 1.2–2.7)*
Specimens were tested in duplicate.
*p <0.01, the unadjusted chi-square or Fisher’s exact test was used for categorical independent variables. Estimation of the 95% conﬁdence interval was performed with exact
binomial methods. Calculations were conducted with SPSS statistical software, version 17.0 (SPSS, Chicago, IL, USA).
a1517 and 9936 sera samples were collected from residents of two villages in Jiangsu province, eastern China, in March 2009 and May 2010, respectively. None of the people
had a history of inﬂuenza vaccination.
bAmong the 1517 and 9936 sera samples, there are 1295 serial sample pairs taken from the same individuals in 2009 and 2010, respectively.
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indeed represent antibodies that can speciﬁcally neutralize
the H9N2 virus but not H3N2, H1N1 or H6N1 inﬂuenza
viruses used as controls. Our result is not unexpected, given
that the H5N1 virus is highly pathogenic and asymptomatic
infection is unlikely. However, infection with the avian H9N2
virus causes only mild symptoms. It is possible that the G1-
like H9N2 virus may be prevalent in the poultry in the area
from where those sera were collected. While only 11 human
cases have been identiﬁed up to date, the avian H9N2 virus
was not considered to infect humans regularly. Because we
found a similar rate of positivity for antibodies against the
seasonal H1N1 virus (Table 1), the detection of antibodies
speciﬁc to the H9N2 virus suggests that natural infection
with this virus in the general population may occur at higher
levels than previously thought. While we have just experi-
enced the swine-origin H1N1 pandemic and continue to clo-
sely watch the activity of the avian H5N1 virus, the potential
for the H9N2 virus or one of its derivatives to cause a pan-
demic should be further assessed.
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Abstract
Dengue is a signiﬁcant mosquito-borne infection in humans, and
its worldwide prevalence is rapidly increasing. In 2010, 83 serum
samples from febrile travellers returning from dengue-endemic
countries to a region in north-eastern Italy, densely infested with
Aedes albopictus, were analysed for dengue virus (DENV). DENV
RNA was detected in 20.5% of patients. By RT-PCR, DENV ser-
otypes 1 and 3 were the most common. DENV must be identi-
ﬁed early in symptomatic travellers returning from high-risk
countries, to prevent outbreaks where potential vectors exist.
Keywords: Dengue virus, imported cases, Italy, laboratory
diagnosis, surveillance, vector-borne
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